FDA committee votes in favour of Pfizer’s RSV vaccine for maternal immunisation
May 19, 2023Research and Development FDA, Immunology, Pfizer, RSV, Vaccine, maternal immunisation
Pfizer has announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) from the US Food and Drug Administration …
FDA approves Abbott’s Assert-IQ insertable cardiac monitor
May 19, 2023Research and Development Abbott, Cardiology, Devices, FDA, heart monitor, medical devices
Abbott has announced that the US Food and Drug Administration (FDA) has granted its clearance for the Assert-IQ insertable cardiac …
Schott Pharma announces pre-filled polymer syringes for deep-cold medication
May 19, 2023Medical Communications Devices, Schott Pharma, deep cold medication, syringe
Germany-based drug delivery solutions company Schott Pharma has announced its pre-fillable syringes (PFS) for drugs requiring deep-cold, such as those …
NHS given guidance on offering genetic testing to stroke patients
May 19, 2023Medical Communications NHS, Neurology, blood clot, genetic testing, stroke
The NHS has been given draft guidance on offering gene tests to patients who have had a stroke caused by …
Is the pharmaceutical sector prepared to face a titanium dioxide ban?
May 19, 2023Manufacturing and Production ACG, EMA, EU, Titanium Dioxide
Dr Subhashis Chakraborty, head of Global Product Management, ACG Capsules In the wake of the ban on titanium dioxide (TiO2) …
NICE recommends Kapruvia for treatment of moderate-to-severe CKD-associated pruritus
May 18, 2023Medical Communications Kapruvia, NICE, Nephrology, chronic kidney disease, pruritus
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics have announced that the National Institute for Health and Care …
US appeals court hears arguments in abortion pill case
May 18, 2023Medical Communications Obstetrics & Gynaecology, abortion, medication abortion, mifepristone, reproduction
The ongoing court battle surrounding the contested approval of mifepristone, one of the drugs used in medication abortions, has now …
Servier and Aitia enter into R&D collaboration for pancreatic cancer using Digital Twins
May 18, 2023Research and Development Aitia, Digital Twins, Oncology, Pancreatic cancer, Servier
French pharmaceutical company Servier and US-based Causal AI and Digital Twins company Aitia have announced a collaboration to create Digital …
Asieris Pharmaceuticals and Uroviu announce strategic collaboration to further develop integrated diagnosis and treatment for bladder cancer
May 18, 2023Research and Development Asieris Pharmaceuticals, Diagnostics, Oncology, Uroviu, bladder cancer, oncology
US-based biopharmaceutical company Asieris Pharmaceuticals and single-use endoscopic platform creator Uroviu have announced that they have entered into a strategic …
Nemours Children’s Health selected to conduct first gene therapy for Morquio A syndrome
May 17, 2023Research and Development Morquio A syndrome, NIH, Nemours Children's Health, Paediatrics, gene therapy
Nemours Children’s Health, based in Delaware, US, has been chosen by the Foundation for the National Institutes of Health (FNIH) …
AstraZeneca announces positive results from phase 3 trial for Tagrisso plus chemotherapy
May 17, 2023Research and Development AstraZeneca, Cancer, Oncology, Tagrisso, chemotherapy
AstraZeneca has announced positive results from the FLAURA2 phase 3 trial which showed that Tagrisso (osimertinib), in combination with chemotherapy, …
NICE recommends nine digital treatment options for depression and anxiety
May 17, 2023Medical Communications NICE, Neurology, anxiety, depression, digital health, mental health
The National Institute for Health and Care Excellence (NICE) has recommended six digitally enabled therapies for adult patients with anxiety …
FDA grants Priority Review for Takeda’s cTTP treatment
May 17, 2023Research and Development Biologics License Application, Cardiology, FDA, Takeda, cTTP
Japanese biopharmaceutical company Takeda has announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application …
RadioMedix and Orano Med complete patient enrolment for neuroendocrine cancer trial
May 16, 2023Medical Communications Oncology, Orano Med, RadioMedix, neuroendocrine cancer, oncology
US-based RadioMedix and French Orano Med, two clinical stage radiopharmaceutical companies, have announced that the last patient has been enrolled …
Nido Biosciences raises $109m in funding for neurological diseases treatments
May 16, 2023Sales and Marketing Financing, Neurology, Nido Biosciences, funding, neurology
US-based clinical-stage company Nido Biosciences has announced that is has received $109m in Seed, Series A and Series B financings, …
Astellas and Sony enter collaborative research agreement
May 16, 2023Research and Development ADC, Astellas Pharma, Oncology, Sony, research agreement
Sony and Astellas Pharma have announced that they have entered into a collaborative research agreement in an attempt to discover …
uniQure announces sale of royalty interest in Hemgenix for up to $400m
May 16, 2023Sales and Marketing Haematology, Hemgenix, haemophilia, royalties, uniQure
uniQure has announced that it has entered a definitive agreement to sell a portion of the royalty rights due to …
LaNova Medicines and AstraZeneca sign global exclusive license agreement for preclinical ADC
May 15, 2023Research and Development ADC, AstraZeneca, LaNova Medicines, License Agreement, Oncology
Chinese biotechnology company LaNova Medicines and UK-based pharma company AstraZeneca have announced that they have signed a global exclusive license …
Relief Therapeutics awarded approval from Swissmedic for new GMP-compliant laboratory
May 15, 2023Research and Development GMP, Relief Therapeutics, Swissmedic, laboratory
Swiss biopharmaceutical company Relief Therapeutics has announced that its state-of-the-art R&D laboratory in Balerna, Switzerland, has been audited and approved …
NICE recommends Hepcludex for NHS use to treat aggressive form of viral hepatitis
May 15, 2023Medical Communications NHS, NICE, Virology, hepatitis
The National Institute for Health and Care Excellence (NICE) has recommended Hepcludex (bulevirtide) for the treatment of chronic hepatitis delta …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
